Canopy Growth Corp
Canopy Growth Corporation, together with its subsidiaries, engages in the production, distribution, and sale of cannabis, hemp, and cannabis-related products in Canada, Germany, and Australia. It operates through four segments: Canada Cannabis, International Markets Cannabis, and Storz & Bickel, and This Works. The company offers dried flower and pre-rolled joints; extracts and concentrates, such… Read more
Canopy Growth Corp (CGC) - Net Assets
Latest net assets as of December 2025: $758.17 Million USD
Based on the latest financial reports, Canopy Growth Corp (CGC) has net assets worth $758.17 Million USD as of December 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($1.11 Billion) and total liabilities ($348.02 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $758.17 Million |
| % of Total Assets | 68.54% |
| Annual Growth Rate | 56.64% |
| 5-Year Change | -86.55% |
| 10-Year Change | 293.6% |
| Growth Volatility | 225.77 |
Canopy Growth Corp - Net Assets Trend (2010–2025)
This chart illustrates how Canopy Growth Corp's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Canopy Growth Corp (2010–2025)
The table below shows the annual net assets of Canopy Growth Corp from 2010 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-03-31 | $487.21 Million | -2.66% |
| 2024-03-31 | $500.51 Million | -34.15% |
| 2023-03-31 | $760.02 Million | -79.01% |
| 2022-03-31 | $3.62 Billion | -0.04% |
| 2021-03-31 | $3.62 Billion | -0.44% |
| 2020-03-31 | $3.64 Billion | -49.76% |
| 2019-03-31 | $7.24 Billion | +482.47% |
| 2018-03-31 | $1.24 Billion | +102.24% |
| 2017-03-31 | $614.74 Million | +396.62% |
| 2016-03-31 | $123.78 Million | +198.93% |
| 2015-03-31 | $41.41 Million | +91.11% |
| 2014-12-31 | $21.67 Million | +465.27% |
| 2014-03-31 | $3.83 Million | +671.25% |
| 2013-03-31 | $497.01K | -7.56% |
| 2012-03-31 | $537.65K | -3.40% |
| 2011-03-31 | $556.60K | -4.14% |
| 2010-03-31 | $580.67K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Canopy Growth Corp's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 1092811808200.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (March 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $8.80 Billion | 1805.45% |
| Other Comprehensive Income | $535.00K | 0.11% |
| Other Components | $2.62 Billion | 537.43% |
| Total Equity | $487.21 Million | 100.00% |
Canopy Growth Corp Competitors by Market Cap
The table below lists competitors of Canopy Growth Corp ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Formosa Taffeta Co Ltd
TW:1434
|
$404.11 Million |
|
Amaroq Ltd.
PINK:AMRQF
|
$404.16 Million |
|
Maharashtra Seamless Limited
NSE:MAHSEAMLES
|
$404.25 Million |
|
Double Medical Technology Inc
SHE:002901
|
$404.40 Million |
|
Pacific Biosciences of California
NASDAQ:PACB
|
$404.05 Million |
|
Shenzhen LeoKing Environmental Group Co. Ltd. A
SHE:301305
|
$404.05 Million |
|
Fuerte Metals Corporation.
V:FMT
|
$404.00 Million |
|
Shanghai Wondertek Software Co Ltd
SHG:603189
|
$403.99 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Canopy Growth Corp's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 500,368,000 to 487,213,000, a change of -13,155,000 (-2.6%).
- Net loss of 598,115,000 reduced equity.
- New share issuances of 385,391,000 increased equity.
- Other comprehensive income increased equity by 16,586,000.
- Other factors increased equity by 182,983,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-598.12 Million | -122.76% |
| Share Issuances | $385.39 Million | +79.1% |
| Other Comprehensive Income | $16.59 Million | +3.4% |
| Other Changes | $182.98 Million | +37.56% |
| Total Change | $- | -2.63% |
Book Value vs Market Value Analysis
This analysis compares Canopy Growth Corp's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.24x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 1.84x to 0.24x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2010-03-31 | $0.58 | $1.07 | x |
| 2011-03-31 | $0.56 | $1.07 | x |
| 2012-03-31 | $0.54 | $1.07 | x |
| 2013-03-31 | $0.50 | $1.07 | x |
| 2014-03-31 | $3.83 | $1.07 | x |
| 2015-03-31 | $1.38 | $1.07 | x |
| 2016-03-31 | $1.61 | $1.07 | x |
| 2017-03-31 | $5.17 | $1.07 | x |
| 2018-03-31 | $6.54 | $1.07 | x |
| 2019-03-31 | $20.60 | $1.07 | x |
| 2020-03-31 | $9.64 | $1.07 | x |
| 2021-03-31 | $9.27 | $1.07 | x |
| 2022-03-31 | $91.58 | $1.07 | x |
| 2023-03-31 | $16.36 | $1.07 | x |
| 2024-03-31 | $6.69 | $1.07 | x |
| 2025-03-31 | $4.53 | $1.07 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Canopy Growth Corp utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -122.76%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -222.35%
- • Asset Turnover: 0.29x
- • Equity Multiplier: 1.88x
- Recent ROE (-122.76%) is below the historical average (-53.91%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2010 | -4.64% | -4903.10% | 0.00x | 1.01x | $-84.98K |
| 2011 | -4.32% | -536.27% | 0.01x | 1.01x | $-79.73K |
| 2012 | -3.98% | 0.00% | 0.00x | 1.01x | $-75.16K |
| 2013 | -13.00% | -1559.07% | 0.01x | 1.02x | $-114.31K |
| 2014 | -24.34% | 0.00% | 0.00x | 1.34x | $-1.32 Million |
| 2014 | -41.22% | -779.58% | 0.04x | 1.20x | $-11.10 Million |
| 2015 | -21.57% | -779.58% | 0.02x | 1.15x | $-13.07 Million |
| 2016 | -2.82% | -27.53% | 0.09x | 1.16x | $-15.87 Million |
| 2017 | -2.70% | -41.63% | 0.06x | 1.10x | $-78.08 Million |
| 2018 | -4.67% | -69.45% | 0.05x | 1.24x | $-170.01 Million |
| 2019 | -9.64% | -296.06% | 0.03x | 1.26x | $-1.37 Billion |
| 2020 | -38.49% | -331.35% | 0.08x | 1.40x | $-1.66 Billion |
| 2021 | -50.12% | -319.20% | 0.08x | 1.96x | $-2.09 Billion |
| 2022 | -8.65% | -65.18% | 0.08x | 1.56x | $-668.40 Million |
| 2023 | -432.23% | -983.68% | 0.14x | 3.22x | $-3.35 Billion |
| 2024 | -131.36% | -221.19% | 0.23x | 2.60x | $-707.31 Million |
| 2025 | -122.76% | -222.35% | 0.29x | 1.88x | $-646.84 Million |
Industry Comparison
This section compares Canopy Growth Corp's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $548,450,613
- Average return on equity (ROE) among peers: -450.37%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Canopy Growth Corp (CGC) | $758.17 Million | -4.64% | 0.46x | $404.06 Million |
| Ascend Wellness Holdings Inc (AAWH) | $142.87 Million | -33.75% | 5.44x | $48.90 Million |
| AB Science S.A (ABSCF) | $10.73 Million | -252.65% | 3.71x | $39.89 Million |
| Alterola Biotech Inc (ABTI) | $4.85K | -2005.32% | 0.49x | $603.58K |
| Aurora Cannabis Inc (ACB) | $2.04 Billion | -34.08% | 0.34x | $199.15 Million |
| Acreage Holdings Inc (ACRDF) | $204.27 Million | -30.85% | 1.41x | $13.48K |
| Acura Pharmaceuticals Inc (ACUR) | $7.90 Million | -63.15% | 1.15x | $13.20K |
| Agra Ventures Ltd. (AGFAF) | $1.51 Million | -44.22% | 0.06x | $298.23K |
| Allergy Therapeutics plc (AGYTF) | $2.07 Million | -2084.75% | 31.32x | $25.30 Million |
| Aida Pharmaceuticals Inc (AIDA) | $6.67 Million | 24.51% | 2.78x | $1.80 |
| Adcock Ingram Holdings Limited (AIHLF) | $3.07 Billion | 20.55% | 0.55x | $85.61 Million |